Physician profile
Robert P Tully
NPI 1013932870
$2,363.21
in general payments reported to CMS, 2019-2025
30 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $287 · 2021: $295 · 2022: $251 · 2023: $273 · 2024: $657 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $708.95 | 2019-2025 | Evenity, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $234.26 | 2019-2024 | |
| Mylan Specialty L.P. | $145.18 | 2022-2024 | Yupelri |
| Nestle Healthcare Nutrition INC. | $129.37 | 2020-2023 | |
| Glaxosmithkline, LLC. | $116.68 | 2021-2024 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $93.58 | 2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $92.78 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $90.93 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $77.57 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $57.36 | 2021-2024 | |
| Lilly USA, LLC | $56.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.33 | 2019-2022 | |
| Dexcom, INC. | $47.71 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $45.92 | 2019-2024 | |
| Edwards Lifesciences Corporation | $45.52 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $44.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $41.80 | 2021-2022 | |
| Biogen, INC. | $37.26 | 2021 | |
| Daiichi Sankyo INC. | $28.11 | 2025 | Injectafer |
| Eisai INC. | $26.25 | 2025 | |
| Neurocrine Biosciences, INC. | $23.37 | 2023 | Ingrezza |
| Grifols USA, LLC | $22.46 | 2021 | |
| Radius Health, INC. | $22.27 | 2023 | Tymlos |
| Renalytix Ai, INC. | $19.61 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.25 | 2022 | |
| Astellas Pharma US INC | $19.10 | 2019 | |
| Insmed, INC. | $19.05 | 2024 | Arikayce |
| Novo Nordisk INC | $16.18 | 2024 | Ozempic, Rybelsus |
| Abbvie INC. | $13.83 | 2024 | |
| Nevro Corp. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tully listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.